JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia

NCT03557970 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Not enough enrollment to determine efficacy

Conditions

Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions

DRUG: Edicotinib
OTHER: Pharmacokinetic Study

Sponsor

OHSU Knight Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]